Treatment of bone loss is now a mature art, and payers are not swayed by esoteric arguments -- what they are responding to is ‘number needed to treat in order to prevent some system cost of treatment.'
Scottsdale, AZ (PRWEB) May 03, 2011
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for osteoporosis therapies.
“In this series of interviews with our panel of rheumatologists and endocrinologists who specialize in the treatment of non-malignant bone loss, we specifically constrain their comments to take cost into consideration,” according to Jeff Berk, the report’s author. “The fact is that osteoporosis is a disease that can be managed by a myriad of therapeutic treatment approaches. Bisphosphonates have been available for 25 years. We have SERMs, HRT, calcitonin, PTH, strontium, calcium, and a host of new therapeutics in the pipeline. Treatment of bone loss is now a mature art, and payers are not swayed by esoteric arguments -- what they are responding to is ‘number needed to treat in order to prevent some system cost of treatment’.”
Thus, this report divides existing and pipeline therapeutics into known and expected cost-of-therapy cohorts, and compares the efficacy, safety and convenience benefits for those therapies that fall into each cohort. Specifically, we compare zoledronic acid (Reclast) vs denosumab (Prolia), marketed oral antiresorptives (branded BPs, generic BPs, SERMs), near-market oral antiresorptives (cathepsin K, strontium, oral calcitonin), and anabolics (teriparatide, anti-sclerostin).
To develop this analysis, entitled “Thought Leader Insight & Analysis: Osteoporosis Q1 2011,” MedPredict conducted primary interviews with U.S.-based and European thought leaders. MedPredict has published over 50 research reports in osteoporosis and maintains ongoing relationships with experts in North America and Western Europe.
Companies mentioned in this report include: Abbott, Amgen, Emisphere, GlaxoSmithKline, Lilly, Merck, Nordic, Novartis, Ono, Pfizer, Piramal, Roche, Servier, Teva, UCB, Unigene, Warner Chilcott, Watson.
This report can be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
For more information contact: